A Phase 1 interventional study of Dasatinib and Bortezomib in Multiple Myeloma, sponsored by Bristol-Myers Squibb. Terminated at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-13.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 215th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 41 in phase 1, and was the 75th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 22 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 94th largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2008, is one of 40 in phase 1, and was the 17th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I dose escalation study
Drug: Dasatinib · Drug: Bortezomib · Drug: Dexamethasone
Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
Also known as: Sprycel, BMS-354825
Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD
Also known as: Velcade®
Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone
MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended MTD is the maximum dose that the participants received.
Time frame: Days 1 to 21
MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone
MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended dose is the maximum dose that the participants received.
Time frame: Days 1 to 21
Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry
S=serum; U=urine; MP=M-protein; ST=soft tissue, PC=plasmacytomas; IF=immunofixation; BL=baseline. RR calculated on best response any time. CR=MP undetectable by IF, ≤5% plasma cells in bone marrow, and no ST PC. VGPR=MP detectable by IF, or ≥90% drop in S MP and U MP\<100 mg/24h. PR= ≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size. MR= ≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC. SD=Not CR, VGPR, PR, or MR. PD= ≥25% rise in S or U M-component; new/increased size of bone lesions, ST PC, or hypercalcemia.
Time frame: Day 1 until last tumor assessment (maximum reached: 9 months)
Duration of Response
Duration of response calculated for those with best response=CR (M-protein \[MP\] undetectable by immunofixation \[IF\], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum \[S\] MP and urine \[U\] MP\<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first.
Time frame: First occurrence of response to disease progression or death, whichever occurred first (maximum reached: 12.2 months)
Progression-free Survival
Progression-free survival was defined as the time from start of treatment until progression or death, whichever occurred first. Participants were to be followed-up for 12 months following the last dose of dasatinib for progression and survival. PFS was analyzed for the all-treated population.
Time frame: Day 1 to disease progression or death, whichever came first (maximum reached: 14 months)
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to or of unknown relationship to study treatment. Grade 3=severe; Grade 4=life-threatening.
Time frame: Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)
| Milestone | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD |
|---|---|---|---|
| Started | 7 | 3 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 7 | 3 | 4 |
| Withdrew: Adverse event unrelated to study drug | 2 | 1 | 1 |
| Withdrew: Study drug toxicity | 3 | 0 | 1 |
| Withdrew: Disease progression | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Maximum clinical benefit | 1 | 0 | 0 |
MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended MTD is the maximum dose that the participants received.
| mg QD | All Treated |
|---|---|
| MTD dasatinib | NA |
| Recommended MTD dasatinib | 140 |
S=serum; U=urine; MP=M-protein; ST=soft tissue, PC=plasmacytomas; IF=immunofixation; BL=baseline. RR calculated on best response any time. CR=MP undetectable by IF, ≤5% plasma cells in bone marrow, and no ST PC. VGPR=MP detectable by IF, or ≥90% drop in S MP and U MP\<100 mg/24h. PR= ≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size. MR= ≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC. SD=Not CR, VGPR, PR, or MR. PD= ≥25% rise in S or U M-component; new/increased size of bone lesions, ST PC, or hypercalcemia.
| Percentage of participants | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD |
|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 |
| Very good partial response (VGPR) | 0 | 0 | 0 |
| Partial response (PR) | 14.3 | 0 | 0 |
| Minimal response (MR) | 0 | 0 | 25 |
| Stable disease (SD) | 57.1 | 0 | 0 |
| Progressive disease (PD) | 14.3 | 33.3 | 0 |
| Unable to determine | 0 | 33.3 | 25 |
| Not reported | 14.3 | 33.3 | 50 |
Duration of response calculated for those with best response=CR (M-protein \[MP\] undetectable by immunofixation \[IF\], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum \[S\] MP and urine \[U\] MP\<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first.
| Months | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD |
|---|---|---|---|
| Partial response (PR) | 5.4 | — | 0 |
| Minimal response (MR) | NA | — | 12.2 |
Progression-free survival was defined as the time from start of treatment until progression or death, whichever occurred first. Participants were to be followed-up for 12 months following the last dose of dasatinib for progression and survival. PFS was analyzed for the all-treated population.
| Months | All Treated |
|---|---|
| Progression-free Survival | 6.3 (2.4 to 14.0) |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to or of unknown relationship to study treatment. Grade 3=severe; Grade 4=life-threatening.
| Participants | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD |
|---|---|---|---|
| Death | 3 | 2 | 2 |
| SAEs | 6 | 2 | 1 |
| Drug-related SAEs | 2 | 0 | 0 |
| Drug-related AEs leading to discontinuation | 3 | 0 | 1 |
| AEs leading to discontinuation | 5 | 1 | 2 |
| AEs | 7 | 3 | 4 |
| AEs, Grades 3 and 4 | 3 | 3 | 4 |
| Drug-related AEs | 6 | 2 | 4 |
| Drug-related AEs, Grades 3 and 4 | 4 | 2 | 4 |
MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended dose is the maximum dose that the participants received.
| mg/m^2 | All Treated |
|---|---|
| MTD of bortezomib | NA |
| Recommended MTD of bortezomib | 1.3 |
Collected over Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dasatinib, 100 mg QD | — | 2/3 (66.7%) | 3/3 (100%) |
| Dasatinib, 140 mg QD | — | 1/4 (25%) | 4/4 (100%) |
| Dasatinib, 50 mg BID | — | 6/7 (85.7%) | 6/7 (85.7%) |
| Event | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Dasatinib, 50 mg BID |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 3/7 |
| PyrexiaGeneral disorders | 1/3 | 0/4 | 0/7 |
| Respiratory tract infectionInfections and infestations | 1/3 | 0/4 | 0/7 |
| Confusional statePsychiatric disorders | 1/3 | 0/4 | 0/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/4 | 0/7 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/3 | 1/4 | 0/7 |
| Pneumocystis jiroveci pneumoniaInfections and infestations | 0/3 | 0/4 | 1/7 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/4 | 1/7 |
| Renal failureRenal and urinary disorders | 0/3 | 0/4 | 1/7 |
| Event | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Dasatinib, 50 mg BID |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/3 | 3/4 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 1/4 | 2/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/3 | 1/4 | 1/7 |
| NauseaGastrointestinal disorders | 0/3 | 0/4 | 4/7 |
| PyrexiaGeneral disorders | 0/3 | 1/4 | 3/7 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/4 | 0/7 |
| ConstipationGastrointestinal disorders | 1/3 | 0/4 | 0/7 |
| Dry mouthGastrointestinal disorders | 1/3 | 0/4 | 0/7 |
| DyspepsiaGastrointestinal disorders | 1/3 | 1/4 | 0/7 |
| DysphagiaGastrointestinal disorders | 1/3 | 0/4 | 0/7 |
| Age, Continuous(Years) | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Total |
|---|---|---|---|---|
| Mean | 72 (64.0 to 74.0) | 74 (57.0 to 75.0) | 59.5 (53.0 to 75.0) | 71 (53.0 to 75.0) |
| Age, Customized(Participants) | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Total |
|---|---|---|---|---|
| 46 to 65 years | 1 | 1 | 3 | 5 |
| 66 to 75 years | 6 | 2 | 1 | 9 |
| Older than 75 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 3 | 6 |
| Male | 5 | 2 | 1 | 8 |
| Race/Ethnicity, Customized(Participants) | Dasatinib, 50 mg BID | Dasatinib, 100 mg QD | Dasatinib, 140 mg QD | Total |
|---|---|---|---|---|
| White | 6 | 3 | 4 | 13 |
| Black or African American | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Other | 1 | 0 | 0 | 1 |
| Not reported | 0 | 0 | 0 | 0 |
The record gives a start of Feb 2008, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dasatinib · Bortezomib · Dexamethasone